Kristi Rosa | Authors

July 14, 2021

Encouraging findings from an ongoing phase 1 trial evaluating an off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy, evaluated in patients with lymphoma.

July 07, 2021

Adding paclitaxel to the combination of trastuzumab and pertuzumab was associated with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer compared with the doublet alone.

June 18, 2021

Results from an observational, multicenter study that evaluated osimertinib reveal encouraging real-world efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer.

June 15, 2021

The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.